Ipo funding is leading the pack in Raleigh-Durham life science

– Debt and equity was the most popular life science funding type in 2021 and 2022, but that has since changed largely due to higher borrowing costs.

– So far in 2024, ipo funding has far surpassed debt and equity and early-stage funding, making ipo funding the most popular funding type for life science in Raleigh-Durham and totaling more than the average ipo funding amount since 2016 of $160 Million.

– Surpassing the average has only occurred 3 times since 2016 (not including 2024). If this trend continues, 2024 will be the first year in recent history that ipo funding was the largest funding source for life science in Raleigh-Durham.